The Cancer Letter

Inside information on cancer research and drug development

NCI Director's Report

NCI raises paylines, commemorates 50th anniversary of the National Cancer Act of 1971

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Pandemic notwithstanding, NCI is on track to reach the 15th percentile for the payline by 2025—a goal set by institute Director Ned Sharpless in response to a deluge of grant applications.

“Congress’s support has allowed NCI to raise the payline for R01 research awards by 35% since 2019. For two consecutive years, we’ve raised grant paylines for [early-stage investigators] as well,” Sharpless said Feb. 11 in his director’s report at a virtual meeting of the National Cancer Advisory Board.

Last year, Sharpless set the goal of reaching the 15th perentile by 2025.

“You can see the [Early Stage Investigator] payline is now 16th percentile. That is the best payline for an R01 out of the NCI in a very long time. And we are also able to sustain continuing awards at 100th percentile.”

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

Obituary

Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
By Melinda Krigel
Obituary

Feng’s team advanced the understanding of biomarkers in prostate cancer

The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.
By NRG Staff
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account